← Back to Search

Alpha-2 Adrenergic Agonist

Topical Apraclonidine for Bell's Palsy

Phase 4
Waitlist Available
Led By Benjamin Greene, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of synkinesis affecting eye movement
Age 18 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - 20 minutes after study drug administration
Awards & highlights

Study Summary

This trial is testing whether apraclonidine can help patients with ocular synkinesis, a condition where the muscles around the eye don't work properly.

Who is the study for?
This trial is for adults over 18 who can give consent and understand English, diagnosed with ocular synkinesis (involuntary eye movement) due to facial nerve issues. It's not for those allergic to Apraclonidine, under 18, on monoamine oxidase inhibitors, or with certain other eye conditions.Check my eligibility
What is being tested?
The study tests the effectiveness of a topical medication called Apraclonidine in treating involuntary eye movements in patients with ocular synkinesis visiting the UAB Facial Nerve Clinic.See study design
What are the potential side effects?
Apraclonidine may cause side effects such as dry mouth, tiredness, drowsiness, headache and possible allergic reactions like itching or swelling.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My eye movement is affected due to synkinesis.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - 20 minutes after study drug administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - 20 minutes after study drug administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Improvement in synkinesis symptoms

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment GroupExperimental Treatment1 Intervention
Participants will receive the study drug, apraclonidine, per its FDA-approved package labelling

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,581 Previous Clinical Trials
2,278,019 Total Patients Enrolled
Benjamin Greene, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
1 Previous Clinical Trials
20 Total Patients Enrolled

Media Library

Apraclonidine (Alpha-2 Adrenergic Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05167760 — Phase 4
Apraclonidine (Alpha-2 Adrenergic Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05167760 — Phase 4
Synkinesis Research Study Groups: Treatment Group
Synkinesis Clinical Trial 2023: Apraclonidine Highlights & Side Effects. Trial Name: NCT05167760 — Phase 4
Synkinesis Patient Testimony for trial: Trial Name: NCT05167760 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are participating within this clinical research?

"At this juncture, the clinical trial is not actively seeking participants. The information was initially posted on February 1st 2023 and last modified on June 8th 2022. For those looking for other studies, 15 trials are accepting synkinesis patients while one study requires Apraclonidine volunteers."

Answered by AI

To what extent has Apraclonidine been explored in scientific literature?

"At present, there is one ongoing clinical trial for Apraclonidine. This study has not progressed to the third and final phase of trials yet. The research centre based in Birmingham Alabama are running this investigation with a single location recruiting participants."

Answered by AI

Are enrollment opportunities still available for this trial?

"This particular trial has stopped enrolling patients, as the last update on clinicaltrials.gov was made on June 8th 2022. However, there are currently 15 studies seeking participants with synkinesis and one study searching for Apraclonidine test subjects actively recruiting."

Answered by AI

Which potential risks should be considered when using Apraclonidine?

"The safety of apraclonidine has been attested by the Phase 4 clinical trial, thus garnering the drug a 3 rating on our scale."

Answered by AI

Who else is applying?

What state do they live in?
Nevada
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I have significant unwanted movement around my eye with mouth movement. No one here will do botox or has any input on how to make this better.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis
Benjamin Greene 2023. "Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05167760.
All > Bells Palsy
~5 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top